Fruquintinib price

Fruquintinib (Fruquintinib) is an innovative oral targeted drug that is widely used to treat patients with advanced gastric cancer or colorectal cancer, especially those with limited response to traditional treatments. As a multi-target small molecule kinase inhibitor, fruquintinib achieves precise intervention in tumors by regulating signaling pathways such as vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), providing patients with new treatment options.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.

What is unique about fruquintinib is its multi-target mechanism of action. By inhibiting key molecules such as VEGFR and EGFR, fruquintinib blocks the blood supply to tumors, limiting their growth and spread. At the same time, the drug also has a direct impact on the proliferation of tumor cells, making it a targeted drug with dual effects. This precise pharmacological mechanism enables fruquintinib to exhibit good efficacy and safety in cancer treatment.

The clinical application of fruquintinib is mainly focused on patients with advanced cancer, especially those whose disease has progressed after standard chemotherapy and trastuzumab treatment. Although its therapeutic effects are encouraging, patients may experience a series of side effects during the use of fruquintinib, including but not limited to fatigue, loss of appetite, hypertension, hand-foot syndrome, gastrointestinal reactions, etc. These side effects need to be promptly monitored and managed while the patient is taking the medication.